Citi lowered the firm’s price target on Ardelyx to $13 from $14 and keeps a Buy rating on the shares. The analyst updated biotechnology models to reflect reported Q4 and 2023 financials.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDX:
- Ardelyx call volume above normal and directionally bullish
- Krispy Kreme upgraded, Altice USA downgraded: Wall Street’s top analyst calls
- Ardelyx initiated with an Outperform at Leerink
- Ardelyx, Inc. Reports Employment Inducement Grants
- Ardelyx appoints Mike Kelliher as EVP, corporate development, strategy
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue